|
Sánchez-Beltrán J., Soler Díaz J., Herraiz C., Olivares C., Cerdido S., Cerezuela-Fuentes P., García-Borrón J.C., Jiménez-Cervantes C. An MGRN1-Based Biomarker Combination Accurately Predicts Melanoma Patient Survival. International Journal of Molecular Sciences. February 2025. 26. 10.3390/ijms26041739
AÑO: 2025; IF: 4.9
|
40004203
|
Cerdido S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, Castejon-Grinan M, Munoz C, Olivares C, Garcia-Borron JC, Jimenez-Cervantes C, Herraiz C. MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42. Cancer Lett. 2024 Jan 28;581:216484. doi: 10.1016/j.canlet.2023.216484. Epub 2023 Nov 25. PubMed PMID: 38008393.
AÑO: 2024; IF: 10.1
|
|
Castejón-Griñán M., Cerdido S., Sánchez-Beltrán J., Lambertos A., Abrisqueta M., Herraiz C., Jiménez-Cervantes C., García-Borrón J.C. Melanoma-associated melanocortin 1 receptor variants confer redox signaling-dependent protection against oxidative DNA damage. Redox Biology. June 2024. 72. 10.1016/j.redox.2024.103135
AÑO: 2024; IF: 11.9
|
|
Cerdido S., Sánchez-Beltrán J., Lambertos A., Abrisqueta M., Padilla L., Herraiz C., Olivares C., Jiménez-Cervantes C., García-Borrón J.C. A Side-by-Side Comparison of Wildtype and Variant Melanocortin 1 Receptor Signaling with Emphasis on Protection against Oxidative Damage to DNA. International Journal of Molecular Sciences. September 2023. 24. 10.3390/ijms241814381
AÑO: 2023; IF: 4.9
|
|
Abrisqueta M, Cerdido S, Sanchez-Beltran J, Martinez-Vicente I, Herraiz C, Lambertos A, Olivares C, Sevilla A, Alonso S, Boyano MD, Garcia-Borron JC, Jimenez-Cervantes C. MGRN1 as a Phenotypic Determinant of Human Melanoma Cells and a Potential Biomarker. Life (Basel). 2022 Jul 26;12(8):1118. doi: 10.3390/life12081118. PubMed PMID: 35892921; PubMed Central PMCID: PMC9331370.
AÑO: 2022; IF: 3.251
|